Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Tillinghast

Allergy & Immunology Saint Louis, MO Medical Doctor

NPI 1447393301 CMS profile 65100

969 N Mason Rd Ste 240, Saint Louis, MO 63141

Open in the dashboard

General payments

$277,801

593 records reported · program years 2019–2025

Research payments

$2,728

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$10,730,179 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jeffrey Tillinghast of Saint Louis, MO is reported in the CMS Open Payments database as having received $277,801 across 593 general payments and $2,728 in research payments paid to them. Separately, studies naming them as principal investigator received $10,730,179 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,425 70
2024 General $255,569 89
2023 General $7,915 153
2022 General $2,714 114
2021 General $5,759 69
2021 Research $2,640 2
2020 General $2,108 27
2019 General $2,311 71
2019 Research $88 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Tillinghast
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Jeffrey Tillinghast were reported at $1,425. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Jeffrey Tillinghast Allergy & Immunology median Middle half National median
2019 $2,311 $594 $163–$1,512 $163
2020 $2,108 $426 $106–$1,233 $114
2021 $5,759 $638 $157–$1,708 $132
2022 $2,714 $790 $205–$1,961 $149
2023 $7,915 $852 $220–$2,147 $160
2024 $255,569 $865 $203–$2,267 $164
2025 $1,425 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Cipla USA Inc. $253,995 7 payments
  2. AstraZeneca Pharmaceuticals LP $4,932 94 payments
  3. Teva Pharmaceuticals USA, Inc. $2,672 5 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $2,671 18 payments
  5. Chiesi USA, Inc. $1,692 3 payments
  6. Genentech USA, Inc. $1,651 20 payments
  7. Novartis Pharmaceuticals Corporation $1,593 26 payments
  8. AstraZeneca UK Limited $1,541 8 payments
  9. GlaxoSmithKline, LLC. $1,518 111 payments
  10. Regeneron Healthcare Solutions, Inc. $845 31 payments
  11. Other $4,690 270 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $258,795 13 payments
  2. Food and Beverage $11,137 553 payments
  3. Travel and Lodging $6,160 20 payments
  4. Consulting Fee $1,637 3 payments
  5. Education $72 4 payments
Products named General payments · program years 2019–2025
  1. BREZTRI $4,476 38 payments
  2. Xolair $1,637 19 payments
  3. DUPIXENT Immunology $1,217 64 payments
  4. DUPIXENT Inflammation And Immunology $762 28 payments
  5. NUCALA $665 46 payments
  6. TRELEGY ELLIPTA $607 46 payments
  7. QBW251 $569 5 payments
  8. Hizentra $462 15 payments
  9. AIRSUPRA $422 23 payments
  10. TAKHZYRO $403 18 payments
  11. Other $5,741 369 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $2,728 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 86 drugs

Part D claims

4,143

Median for Allergy/ Immunology: 449

Drug cost

$788,880

Median for Allergy/ Immunology: $169,700

Branded share of claims

28.8%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 43 $212,490
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 117 $152,624
Dupixent Syringe Dupilumab Brand 24 $87,610
Breo Ellipta Fluticasone/Vilanterol Brand 98 $68,819
Eliquis Apixaban Brand 60 $45,696
Ozempic Semaglutide Brand 35 $43,446
Spiriva Respimat Tiotropium Bromide Brand 45 $31,371
Farxiga Dapagliflozin Propanediol Brand 25 $28,019
Symbicort Budesonide/Formoterol Fumarate Brand 40 $18,626
Arnuity Ellipta Fluticasone Furoate Brand 29 $13,129

The 10 drugs with the highest cost, of 86 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$111,164

Of which drugs: $25,554

Medicare patients

479

Average age 75

Services billed

4,246

302 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 50%
Osteoporosis 23%
Diabetes 19%
Ischemic heart disease 19%
Depression 18%
Cancer 17%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 74 75 $21,301
Vaccine for influenza for injection into muscle 90653 Office 47 47 $3,764

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $318
  • GENZYME CORPORATION $24
$342 67 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $272
$272 — —
NUCALA
  • GlaxoSmithKline, LLC. $159
$159 — —
XOLAIR
  • Genentech USA, Inc. $68
  • Novartis Pharmaceuticals Corporation $65
$132 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $39
  • Amgen Inc. $27
$66 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

596 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record